Abstract: Screening methods for identifying compounds that bind to or activate corticotropin releasing factor2 receptors (CRF2R) and regulate or potentially regulate skeletal muscle mass or function in vivo are disclosed. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRF2Rs or of CRF2R signal transduction pathways, increase CRF2R or increase CRF expression are provided. Pharmaceutical compositions comprising CRF2R agonists, antibodies to CRF2R and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using CRF2R as the target for intervention and methods for treatment of muscular dystrophies are described.
Type:
Grant
Filed:
August 27, 2003
Date of Patent:
June 20, 2006
Assignee:
The Procter & Gamble Company
Inventors:
Robert Joseph Isfort, Russell James Sheldon
Abstract: Methods are provided that are useful in assaying compounds for cognitive enhancing properties, anxiolytic properties, hypnotic properties, or antidepressant properties. These methods involve determining the in vitro efficacy and EC50 of the compounds at defined series of cloned GABAA subtype receptors composed of specific variants of ?, ?, and ? subunits in order to develop and an activity profile for each compound. Optionally, the binding affinities of the compounds at GABAA receptors are also determined. As an additional step the in vivo effects of the compounds may be tested in animal models.
Type:
Grant
Filed:
November 9, 2001
Date of Patent:
June 13, 2006
Assignee:
Neurogen Corporation
Inventors:
John Tallman, Dorothy Gallager, Kenneth Shaw, Geoffrey White, Marci Crandall, James Cassella, Lavanya Rajachandran, Pamela Albaugh
Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
Type:
Grant
Filed:
September 11, 2002
Date of Patent:
June 13, 2006
Assignee:
North Shore-Long Island Jewish Research Institute
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
November 19, 2001
Date of Patent:
June 6, 2006
Assignee:
Genentech, Inc.
Inventors:
Avi J. Ashkenazi, Kevin P. Baker, David Botstein, Luc Desnoyers, Dan L. Eaton, Napoleone Ferrara, Sherman Fong, Hanspeter Gerber, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Ivar J. Kljavin, Mary A. Napier, James Pan, Nicholas F. Paoni, Margaret Ann Roy, Timothy A. Stewart, Daniel Tumas, Colin K. Watanabe, P. Mickey Williams, William I. Wood, Zemin Zhang
Abstract: A novel receptor-type protein tyrosine phosphatase-? (RPTP?) protein or glycoprotein and the DNA coding therefor is expressed in a wide variety of mammalian tissues. The RPTP? protein or glycoprotein may be produced by recombinant means. Antibodies to the protein, methods for measuring the quantity of the protein, methods for screening compounds, such as drugs, which can bind to the protein and inhibit or stimulate their enzymatic activity, are provided. Further, methods for inhibiting homophilic binding of Type II RPTP, especially RPTP? molecules are provided.
Type:
Grant
Filed:
October 1, 2001
Date of Patent:
June 6, 2006
Assignees:
New York University, Max Planck Gesellschaft Forgerung der Wissenschaften
Inventors:
Joseph Schlessinger, Jan M. Sap, Axel Ullrich, Wolfgang Vogel, Miriam Fuchs
Abstract: The present invention relates to a newly identified receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders, specifically, cardiovascular diseases, including congestive heart failure. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.
Type:
Grant
Filed:
February 13, 2002
Date of Patent:
June 6, 2006
Assignee:
Millennium Pharmaceuticals, Inc.
Inventors:
Maria Alexandra Glucksmann, Fong-Ying Tsai
Abstract: The invention is a treatment for increasing the bone mass or preventing bone loss in an individual afflicted with a bone disease which includes administering to the individual a morphogen in a therapeutically effective amount so as to maintain or stimulate bone formation.
Type:
Grant
Filed:
September 13, 2001
Date of Patent:
June 6, 2006
Assignee:
Curis, Inc.
Inventors:
Thangavel Kuberasampath, Charles M. Cohen, Herrmann Oppermann, Engin Ozkaynak, David C. Rueger, John E. Smart, Roy H. L. Pang
Abstract: The present invention relates to nucleic acids encoding peripheral-type benzodiazepine receptor (PBR)-associated proteins (PAPs), and nucleic acids that hybridize or are variant of nucleic acids encoding the peripheral-type benzodiazepine receptor (PBR)-associated proteins (PAPs), which are capable of encoding proteins that regulate the function of PBRs affecting both steroid biosynthesis and mediating cholesterol delivery as well as other PBR-mediated functions.
Abstract: The present invention provides novel polynucleotides encoding HGRA4 polypeptides, fragments and homologues thereof. The present invention also provides novel polynucleotides encoding a HGRA4 splice variant, HGRA4sv. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGRA4 and HGRA4sv polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
Type:
Grant
Filed:
February 13, 2002
Date of Patent:
June 6, 2006
Assignee:
Bristol-Myers Squibb Company
Inventors:
John N. Feder, Liana Lee, Jian Chen, Nathan O. Siemers, Han Chang
Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the nuclear hormone receptor peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the nuclear hormone receptor peptides, and methods of identifying modulators of the nuclear hormone receptor peptides.
Type:
Grant
Filed:
May 4, 2004
Date of Patent:
May 30, 2006
Assignee:
Applera Corporation
Inventors:
Ming-Hui Wei, Jane Ye, Chunhua Yan, Karen A. Ketchum, Valentina Di Francesco, Ellen M. Beasley
Abstract: The present invention provides polynucleotides encoding potassium channels as well as methods of using the potassium channels to treat and diagnose diabetes and a predisposition for diabetes.
Type:
Grant
Filed:
June 10, 2003
Date of Patent:
May 30, 2006
Assignee:
Metabolex, Inc.
Inventors:
Jeffrey D. Johnson, John F. Palma, Anthony C. Schweitzer, John E. Blume
Abstract: The present invention makes available an optimal concentration of a hedgehog polypeptide for modulating growth and/or cartilage production by chondrocytes. The present invention allows for improvements in the culturing of chondrocytes to develop cartilaginous tissue ex vivo suitable for implantation to replace damaged or deteriorated cartilage in a patient.
Type:
Grant
Filed:
April 27, 2001
Date of Patent:
May 30, 2006
Assignee:
Curis, Inc.
Inventors:
Karin Kellner, Kurt Lang, Apollon Papadimitriou, Ulrike Leser-Reiff, Michaela Schultz, Torsten Blunk, Achim Goepferich
Abstract: TR7 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing TR7 polypeptides and polynucleotides in the design of protocols for the treatment of chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (such as inflammatory bowel disease and psoriasis), transplant rejection, graft versus host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, bone diseases, cancer (such as lymphoproliferative disorders), atherosclerosis, and Alzheimers disease, among others and diagnostic assays for such conditions.
Type:
Grant
Filed:
September 15, 2003
Date of Patent:
May 23, 2006
Assignee:
SmithKline Beecham Corporation
Inventors:
Keith Charles Deen, Mark R. Hurle, Peter Young, Kong B. Tan
Abstract: A protocol of activating and administering human blood cells so that bone marrow histology and/or blood cell counts of patients suffering from aplastic anemia approach normal. The protocol includes culturing the blood cells in the presence of a cytokine and an ionophore. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. 37 C.F.R. ยง 1.72(b).
Abstract: The invention provides isolated nucleic acid and amino acid sequences of KCNQ5, antibodies to KCNQ5, methods of detecting KCNQ5, methods of screening for potassium channel activators and inhibitors using biologically active KCNQ5, and kits for screening for activators and inhibitors of voltage-gated potassium channels comprising KCNQ5.
Abstract: The present invention is directed generally to methods and composition for monitoring the processing of epitope-tagged beta-APP. More specifically, the present invention relates to the use of such methods and composition for monitoring responses of cells expressing such epitope-tagged beta-APP or fragments thereof or cell free systems containing the epitope-tagged polypeptides to therapy of diseases associated with an altered metabolism of the beta amyloid precursor protein (APP), and for screening and evaluation of potential drugs for the treatment of these disorders, including Alzheimer's disease (AD).
Type:
Grant
Filed:
December 20, 2002
Date of Patent:
May 23, 2006
Assignee:
Bristol-Myers Squibb Company
Inventors:
Dietmar A. Seiffert, Thomas J. Mitchell
Abstract: A gene for type C Niemann-Pick disease (NP-C) is disclosed, along with the amino acid sequence of the encoded peptide. Applications which are made possible by the present invention include detection of NP-C carriers and diagnosis of NP-C sufferers. The murine ortholog of the human gene is also disclosed.
Type:
Grant
Filed:
July 29, 2002
Date of Patent:
May 16, 2006
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Eugene D Carstea, Danilo A. Tagle, Jill A. Morris, Peter G. Pentchev, William J. Pavan, Melissa A. Ashlock, Stacie K. Loftus, Jessie Gu
Abstract: A human EMAP III polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for preventing and/or treating neoplasia. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed.
Abstract: The present invention relates to a pharmaceutical composition containing a mixture of stable folding variants of recombinant bone morphogenic proteins (rBMPs) and its use in therapy, especially in the treatment of orthopaedic and dental patients. Specifically, the present invention relates to a pharmaceutical composition containing a mixture of stable folding variants of at least two rBMPs or their monomers or mutants in a suitable carrier system.
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
November 19, 2001
Date of Patent:
May 2, 2006
Assignee:
Genentech, Inc.
Inventors:
Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood